Business, energy, technology, markets and global industry news from Business News Today

β-lactamase inhibitors

PharmaDeviceNews β-lactamase inhibitors
Representative image: A clinical research laboratory setting illustrates Meiji Seika Pharma’s nacubactam Phase III progress, as the novel β-lactamase inhibitor advances the fight against complicated urinary tract infections, acute pyelonephritis and antimicrobial resistance.
Pharma & Biotech

Nacubactam trial win gives Meiji Seika Pharma a stronger AMR case, but approval hurdles remain

Antibiotic resistance needs new tools. Meiji Seika Pharma’s nacubactam now has Phase III data, but regulators must judge its real-world fit.

Read More